Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Kuijper, Dianne C."'
Autor:
Dijkstra, Francis M., van de Loo, Aurora J.A.E., Abdulahad, Smedra, Bosma, Else R., Hartog, Mitch, Huls, Hendrikje, Kuijper, Dianne C., de Vries, Esther, Solanki, Bhavna, Singh, Jaskaran, Aluisio, Leah, Zannikos, Peter, Stuurman, Frederik E., Jacobs, Gabriël E., Verster, Joris C., Afd Pharmacology, dIRAS RA-1, LS communicatie- en informatiewetenschap, One Health Toxicologie, LS IRAS Tox Algemeen, ILS L&C, Pharmacology, Institute for Risk Assesment Sciences
Publikováno v:
Journal of Psychopharmacology, 36(5), 614-625. SAGE PUBLICATIONS LTD
Journal of Psychopharmacology, 36(5), 614. SAGE Publications Ltd
Journal of Psychopharmacology, 36(5), 614. SAGE Publications Ltd
Background: Intranasal esketamine demonstrates rapid improvement of depressive symptoms. However, transient adverse effects (dissociation, sedation and dizziness) may occur, which could impact driving performance. Aims: To evaluate the effects of 84
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37d11cbc804e0e51bf739b1ea4d84983
https://dspace.library.uu.nl/handle/1874/424463
https://dspace.library.uu.nl/handle/1874/424463
Autor:
Dijkstra FM; Centre for Human Drug Research (CHDR), Leiden, The Netherlands.; Department of Psychiatry, Leiden University Medical Centre (LUMC), Leiden, The Netherlands., van de Loo AJ; Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands.; Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands., Abdulahad S; Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands., Bosma ER; Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands., Hartog M; Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands., Huls H; Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands., Kuijper DC; Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands.; Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands., de Vries E; Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands., Solanki B; Janssen Research & Development, La Jolla, CA, USA., Singh J; Janssen Research & Development, La Jolla, CA, USA., Aluisio L; Janssen Research & Development, La Jolla, CA, USA., Zannikos P; Janssen Research & Development, LLC, Raritan, NJ, USA., Stuurman FE; Centre for Human Drug Research (CHDR), Leiden, The Netherlands., Jacobs GE; Centre for Human Drug Research (CHDR), Leiden, The Netherlands.; Department of Psychiatry, Leiden University Medical Centre (LUMC), Leiden, The Netherlands., Verster JC; Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands.; Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.; Centre for Human Psychopharmacology, Swinburne University, Melbourne, Australia.
Publikováno v:
Journal of psychopharmacology (Oxford, England) [J Psychopharmacol] 2022 May; Vol. 36 (5), pp. 614-625. Date of Electronic Publication: 2022 Feb 25.